Lasa Supergenerics Ltd

Lasa Supergenerics Annual Report

Lasa Supergenerics Ltd has submitted its 11th Annual Report for the financial year 2025-26. The Annual General Meeting is scheduled for September 30, 2026.

Lasa Supergenerics Annual General Meeting

Lasa Supergenerics Limited has issued a notice for its Annual General Meeting to be held on September 30, 2026, featuring seven agenda items.

Lasa Supergenerics Board Meeting Outcome

Lasa Supergenerics announced the outcome of its board meeting held on September 09, 2026. The board approved the notice for the 11th Annual General Meeting.

Lasa Supergenerics Management Change

Mr. Ganesh Potdar has resigned as Additional and Whole-time Director of Lasa Supergenerics Limited, effective August 25, 2026. The company officially notified the exchanges.

Lasa Supergenerics Q1 FY27 Results: Net Loss of ₹3.6 Cr, Loss Narrows

Lasa Supergenerics Ltd reported revenue from operations of ₹1.2 Cr (-94.0% YoY) and a net loss of ₹3.6 Cr for Q1 FY27.

Key figure

Net loss ₹3.6 Cr

Lasa Supergenerics Board Meeting Date

Lasa Supergenerics has scheduled a board meeting for August 14, 2026. The board will consider the unaudited financial results for the quarter ended June 30, 2026.

Lasa Supergenerics Other Announcement

Lasa Supergenerics submitted its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report details governance compliance and historical penalties paid for procedural delays.

Lasa Supergenerics Other Announcement

Lasa Supergenerics Limited disclosed Related Party Transactions totaling 35.36 for the period ending March 2026. The report ensures regulatory compliance and transparency regarding promoter-related dealings.

Value

₹35.36 Cr

Execution

Quarter and year ended March 31, 2026

Lasa Supergenerics Financial Results

Lasa Supergenerics reported its audited FY2026 financial results following a significant fire incident. The results carry a modified audit opinion due to asset impairment uncertainties.

Lasa Supergenerics Q4 FY26 Results: Net Loss of ₹4.2 Cr, Loss Narrows

Lasa Supergenerics Ltd reported revenue from operations of -₹0.1 Cr and a net loss of ₹4.2 Cr for Q4 FY26.

Key figure

Net loss ₹4.2 Cr

Lasa Supergenerics Financial Results

Lasa Supergenerics reported annual total income of ₹25.34 Crore for FY 2026. The company posted a net loss of ₹34.09 Crore following a significant fire incident.

Value

₹25.34 Cr

Lasa Supergenerics Board Meeting Date

Lasa Supergenerics scheduled a board meeting for May 29, 2026, to approve audited financial results. Trading window remains closed until 48 hours post-declaration.

Lasa Supergenerics Other Announcement

Lasa Supergenerics Limited submitted its SDD Compliance Certificate for the quarter ended March 31, 2026. The company confirmed the maintenance of a Structured Digital Database in compliance with SEBI PIT Regulations, reporting two required events during the period with no non-compliances observed.

Lasa Supergenerics Debt & Borrowing

Lasa Supergenerics Limited has declared that it does not fall under the 'Large Corporate' category as per SEBI's framework for fund raising via debt securities. This regulatory disclosure confirms the company's non-applicability to specific debt-raising norms mandated for larger entities.

Lasa Supergenerics Q3 FY26 Results: Net Loss of ₹2.6 Cr

Lasa Supergenerics Ltd reported a net loss of ₹2.6 Cr for Q3 FY26.

Key figure

Net loss ₹2.6 Cr